GeneTex's KO/KD-Validated Antibodies for EMT Research
Epithelial-mesenchymal transition (EMT) is a process whereby largely adherent and polarized epithelial cells acquire the phenotype of more mobile
mesenchymal cells. EMT not only facilitates morphogenesis during embryonic development but also promotes invasion and metastasis in tumors.
Pathological EMT is associated with E-cadherin repression, which has been shown to contribute to tumor progression. Several oncogenic pathways
(e.g., TGF-beta, Wnt/beta-catenin, integrins, and Notch) have been reported to induce EMT via cytoskeleton rearrangement and activation of
E-cadherin repressors, including Snail, Slug, SIP1, ZEB1, and TCF3.
- Cited and independently reviewed
- Validated for multiple applications: WB, ICC/IF, IHC-P, IP, ELISA, ChIP
- Validated by Knockout/Knockdown using CRISPR- or RNAi-mediated technologies
Please see the highlighted products below.
|E-Cadherin antibody (GTX100443)||ZO-1 antibody [N1N2], N-term (GTX108613)||Cytokeratin 8 antibody [N1C1] (GTX112975)|
|Vimentin antibody (GTX100619)||alpha-Smooth Muscle Actin antibody (GTX100034)||N-Cadherin antibody (GTX127345)|